关键信息
-
基因名
CPA3
- 应用
-
别名
CPA3；CYP2A3；Cytochrome P450 2A6
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15088
-
表达区间
110-417aa
-
氨基酸序列
IPGRHSYAKYNNWEKIVAWTEKMMDKYPEMVSRIKIGSTVEDNPLYVLKIGEKNERRKAIFTDCGIHAREWVSPAFCQWFVYQATKTYGRNKIMTKLLDRMNFYILPVFNVDGYIWSWTKNRMWRKNRSKNQNSKCIGTDLNRNFNASWNSIPNTNDPCADNYRGSAPESEKETKAVTNFIRSHLNEIKVYITFHSYSQMLLFPYGYTSKLPPNHEDLAKVAKIGTDVLSTRYETRYIYGPIESTIYPISGSSLDWAYDLGIKHTFAFELRDKGKFGFLLPESRIKPTCRETMLAVKFIAKYILKHTS
-
分子量
38.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
The CPA3 protein, or Carboxypeptidase A3, is an important member of the carboxypeptidase family of enzymes, which play crucial roles in various physiological processes, including protein maturation, processing of bioactive peptides, and immune responses. Originally identified in mast cells, CPA3 has garnered research interest due to its involvement in allergic responses and inflammatory diseases. Its unique substrate specificity distinguishes CPA3 from other carboxypeptidases, making it a potential target for understanding the mechanisms underlying mast cell-related conditions. Recent advances in molecular biology and genetic engineering have facilitated the study of CPA3’s structure and function, leading to insights into its enzymatic activity and regulatory mechanisms. Researchers are particularly focused on understanding how CPA3 contributes to the modulation of inflammatory mediators and its implications in conditions such as asthma and other allergic disorders. Furthermore, the potential of CPA3 as a biomarker for mast cell-related diseases is being explored, offering new avenues for diagnosis and therapeutic intervention. The ongoing investigation into CPA3’s role in health and disease aims to provide a comprehensive understanding of its significance in immunology and disease pathology, ultimately informing the development of targeted therapeutic strategies.
